The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
This partnership has led to a 10% boost in delivery speed
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Enabling a new era in minimally invasive obesity treatment across Europe
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
Subscribe To Our Newsletter & Stay Updated
